TWC BioSearch
CYCLIC NUCLEOTIDES


cAMP (low pH)
Colorimetric ELISA

DE0350

<0.45 pmol/mL

0.5-5000 pmol/mL

96

cAMP
Colorimetric ELISA

DE0400

<0.4 pmol/mL

0.5-5000 pmol/mL

96

cGMP (low pH)
Colorimetric ELISA

DE0550

<0.09 pmol/mL

0.8-500 pmol/mL

96

cGMP
Colorimetric ELISA

DE0600

<0.4 pmol/mL

0.8-500 pmol/mL

96

EI-117
Ro 20-1724
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone
99%, MW=278.4 [29925-17-5] Storage: RT
Selective inhibitor of cAMP-specific phosphodiesterase (PDE IV, IC50=2 µM)60,61,62. The use of this agent in a cell culture model of theblood-brain barrier has recently been described63.
100 mg
1 g

PD-175
Rolipram
98%, MW=275.4 [61413-54-5] Storage: RT
Selective inhibitor of cAMP-specific phosphodiesterase (PDE IV, IC50=1 µM)61,64. A rolipram insensitive PDE IV subtype has recently beendescribed65.
10 mg
50 mg

PD-180
Trequinsin (HL 725)
98%, MW=442.0 [78416-81-6] Storage: RT
A selective, ultrapotent inhibitor of cGMP-inhibited phosphodiesterase (PDE III, IC50=0.3nM)66.
10 mg
5 x 10 mg

PD-185
Vinpocetine
98%, MW=350.5 [42971-09-5] Storage: RT
Selective inhibitor of Ca2+/calmodulin-dependent phosphodiesterase (PDE I, IC50=20µM)56,67.
20 mg
100 mg

PD-190
Zaprinast (M&B 22948)
98%, MW=271.3 [37762-06-4] Storage: RT
Selective inhibitor of cGMP specific phosphodiesterase (PDE V, IC50=0.8 µM)68,69. Increases cGMP levels in SHR plasma. Reversesnitroglycerin tolerance in vitro71.
20 mg
100 mg

PD-195
Zardaverine
98%, MW=268.2 [101975-10-4] Storage: RT
Selective, dual inhibitor of PDE III and IV (IC50s=2.5 and 1.1 µMrespectively)72. Anti-allergic activity72.
5 mg
25 mg


PROTEINS

SE-103
Phosphodiesterase (from bovine brain)
3', 5'-cyclic-nucleotide phosphodiesterase
(EC 3.1.4.17) [9040-59-9] Storage: -20°C
Supplied partially purified, lyophilized. Specific activity: 1-5 U/mg protein. One unitwill hydrolyze 1 µmol 3',5'-cAMP to 5'-AMP per minute at pH 7.5 and 30°C.
0.25 U
1 U


REFERENCES

1. R.B. Meyer and J.P. Miller Life Sci. 1974 14 1019

2. Y.-J. Hei et al. Mol. Pharmacol. 1991 39 233

3. M. Sandberg et al. Biochem J. 1991 279 521

4. L.H. Botelho et al. Methods Enzymol. 1988 159 159

5. P. Schaap et al. J. Biol. Chem. 1993 268 6323

6. T. Braumann et al. Biochim. Biophys. Acta 1986 871199

7. J.D. Rothermel et al. Biochem. J. 1988 251 757

8. M. Mock and A. Ullman Trends Microbiol. 1993 1 187

9. A.A. Weiss and E.L. Hewlett Annu. Rev. Microbiol. 1986 40661

10. D.L. Confer and J.W. Eaton Science 1982 217 948

11. S.T. Holgate et al. Proc. Natl. Acad. Sci. USA 1980 776800

12. K.B. Seamon and J.W. Daly Adv. Cyclic. Nucl. Res. 1986 201

13. A. Laurenza et al. Trends Pharmacol. Sci. 1989 10442

14. N.J. De Souza et al. Med. Res. Rev. 1983 3 201

15. A. Laurenza et al. Mol. Pharmacol. 1987 32 133

16. A.L. Alonzo-Gomez and P.M. Iuvone J. Neurochem. 1995 651054

17. D.N. Harris et al. J. Cyclic Nucl. Res. 1979 5 125

18. J. Tamaoki et al. Prostaglandins 1993 45 363

19. W.X. Shi et al. J. Neurosci. 1992 12 2433

20. D. Dixon et al. J. Neurosci. 1989 9 4246

21. E. Butt et al. Eur. J. Pharmacol. 1994 269 265

22. H.S. Ahn et al. Biochem. Pharmacol. 1989 38 3331

23. S.G. Francis et al. Mol. Pharmacol. 1988 34 506

24. K.D. Schultz et al. Naunyn-Schmiedeberg's Arch. Pharmacol. 1979306 1

25. D.C. Sane et al. Biochem. Biophys. Res. Commun. 1989 165708

26. M. Moretto et al. Endocrinology 1993 133 5

27. B.E. Van Uffelen et al. J. Leukoc. Biol. 1996 60 94

28. M. Nakazawa et al. Eur J. Pharmacol. 1994 253 179

29. S.D. Meriney et al. Nature 1994 371 812

30. B. Brüne and V. Ullrich Mol. Pharmacol. 1991 39671

31. A. Schrammel et al. Mol. Pharmacol. 1996 50 1

32. J. Garthwaite et al. Mol. Pharmacol. 1995 48 184

33. S. Cellek et al. Br. J. Pharmacol. 1996 118 137

34. M.A. Moro et al. Proc. Natl. Acad Sci. USA 1996 931480

35. F. Brunner et al. J. Pharmacol. Exp. Ther. 1996 27748

36. A. Mülsch et al. Naunyn-Schmiedeberg's Arch. Pharmacol. 1989340 119

37. J.H. Fleisch et al. J. Pharmacol. Exp. Ther. 1984 229681

38. M.G. Currie et al. Proc. Natl. Acad. Sci. USA 1992 89947

39. S. Schulz et al. Cell 1990 63 941

40. S. Schulz et al. J. Biol. Chem. 1992 267 16019

41. M.S. Wolin et al. J. Biol. Chem. 1982 257 13312

42. J.A. Beavo Adv. Second Messengers Phosphoprotein Res. 198822 1

43. M.D. Houslay and J.A. Beavo, eds. Isozymes of CyclicNucleotide Phosphodiesterases, John Wiley & Sons, 1990

44. J.A. Beavo and D.H. Reifsnyder Trends Pharmacol. Sci. 199011 150

45. C.D. Nicholson et al. Trends Pharmacol. Sci. 1991 12 19

46. H. Hidaka et al. Adv. Cyclic Nucleotide Res. 1984 16245

47. R.E. Weishaar et al. Biochem. Pharmacol. 1986 35787

48. D.R. Newell et al. Biochem. Pharmacol. 1986 35 3871

49. T. Podzuweit et al. Cell. Signal. 1995 7 733

50. P.F. Mery et al. Mol. Pharmacol. 1995 48 121

51. M. Bessodes et al. Biochem. Pharmacol. 1982 31 879

52. G.S. Ahluwalia et al. Biochem. Pharmacol. 1982 31665

53. C. Tomes et al. Cell. Signal. 1993 5 615

54. J.A. Beavo et al. Mol. Pharmacol. 1970 6 597

55. J.N. Wells and J.R. Miller Methods Enzymol. 1988 159489

56. H.S. Ahn et al. Biochem. Pharmacol. 1989 38 3331

57. S.A. Harrison et al. Mol. Pharmacol. 1986 29 506

58. M. Hagiwara et al. J. Pharmacol. Exp. Ther. 1984 228467

59. M. Holck et al. J. Cardiovasc. Pharmacol. 1984 6520

60. H. Sheppard et al. Adv. Cyclic Nucleotide Res. 1972 1103

61. M.L. Reeves et al. Biochem. J. 1987 241 535

62. Y. Katano and M. Endoh Biochem. Biophys. Res. Commun. 1990167 123

63. L.L. Rubin et al. J. Cell Biol. 1991 115 1725

64. H.H. Schneider et al. Eur. J. Pharmacol. 1986 127 105

65. J.B. Moore Jr. et al. Biochem. Pharmacol. 1991 42679

66. D. Rupert and K.U. Weithmann Life Sci. 1982 31 2037

67. M. Hagiwara et al. Biochem. Pharmacol. 1984 33 453

68. P.G. Gillespie et al. Mol. Pharmacol. 1989 36 773

69. F. Burns et al. Biochem. J. 1992 238 487

70. R.L. Dundore et al. Eur. J. Pharmacol. 1993 249 293

71. E.D. Pagani et al. Eur. J. Pharmacol. 1993 243 141

72. D.C. Underwood et al. J. Pharmacol. Exp. Ther. 1994 270250


 

TWC Biosearch International

This page is  best viewed with ANY browser.